

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On May 2, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]
Susan L. Johnson

PATENT
Attorney Docket No.: 011823-004920US
Client Reference No.: PDL0049-20

COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

J. YUN TSO

Application No.: 09/618,380

Filed: July 18, 2000

For: HUMANIZED ANTIBODIES
AGAINST CD3

Confirmation No.: 9002

Examiner: L. Helms

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant

information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please deduct any additional fees from, or credit any overpayment to Deposit Account No. 20-1430.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:sjj

61011069

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/618,380
				Filing Date	July 18, 2000
				First Named Inventor	TSO, J. YUN
				Art Unit	1642
				Examiner Name	L. Helms
Sheet	2	of	3	Attorney Docket Number	011823-004920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AA	ALEGRE et al., "Effect of a Single Amino Acid Mutation on the Activating and Immunosuppressive Properties of a "Humanized" OKT3 Monoclonal Antibody," <u>J. Immunology</u> , 148(11):3461-3468 (1992).	<input type="checkbox"/>	
	AB	BURGERS et al., "The challenges of HIV vaccine development and testing," <u>Best Practice and Research Clinical Obstetrics and Gynaecology</u> , 19:277-291 (2005).	<input type="checkbox"/>	
	AC	COLE et al., "HuM291, A Humanized Anti-CD3 Antibody, Is Immunosuppressive to T cells while Exhibiting Reduced Mitogenicity In Vitro," <u>Transplantation</u> , 68(4):563-571 (1999).	<input type="checkbox"/>	
	AD	CHATENOUD et al., "In-vivo anti-CD3 treatment of autoimmune patients," <u>Lancet</u> , 1(8655):164 (1989).	<input type="checkbox"/>	
	AE	FANGER et al., "Bispecific antibodies for targeted cellular cytotoxicity," <u>Trends in Biotech.</u> , 9(11):375-380 (1991).	<input type="checkbox"/>	
	AF	HOLLIGER et al., "Engineering bispecific antibodies," <u>Curr. Opin. Biotech.</u> , 4(4):446-449 (1993).	<input type="checkbox"/>	
	AG	NOLAN et al., "Bifunctional antibodies: concept, production and applications," <u>Biochem. Biophys. Acta</u> , 1040(1):1-11 (1990).	<input type="checkbox"/>	
	AH	OWENS et al., "Minireview, The genetic engineering of monoclonal antibodies," <u>J. Immunol. Methods</u> , 168(2):149-165 (1994).	<input type="checkbox"/>	
	AI	Wikipedia encyclopedia, 2006, "The Immune System, pages 1-12.	<input type="checkbox"/>	
	AJ	WINTER et al., "Humanized Antibodies," <u>Trends in Pharmacol. Sci.</u> , 14(5):139-143 (1993).	<input type="checkbox"/>	
	AK	WINTER et al., "Humanized antibodies," <u>Immunology Today</u> , 14(6):243-246 (1993).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				<i>Application Number</i>	09/618,380
				<i>Filing Date</i>	July 18, 2000
				<i>First Named Inventor</i>	TSO, J. YUN
				<i>Art Unit</i>	1642
				<i>Examiner Name</i>	L. Helms
Sheet	3	of	3	<i>Attorney Docket Number</i>	011823-004920US

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.